High-grade Lung Adenocarcinoma with Fetal Lung-like Morphology: Clinicopathologic, Immunohistochemical, and Molecular Analyses of 17 Cases
Overview
Authors
Affiliations
Low-grade lung adenocarcinoma of fetal lung type, which is well characterized by its unique clinicopathologic and molecular features, is recognized as a distinct variant of lung cancer. In contrast, high-grade lung adenocarcinoma with fetal lung-like morphology (HG-LAFM) has not been studied widely. To characterize this subset better, we analyzed 17 high-grade adenocarcinomas with at least focal component resembling a developing epithelium in the pseudoglandular phase of the fetal lung. These rare (ca. 0.4%) carcinomas occurred predominantly in elderly men with a heavy smoking history, who showed elevated serum α-fetoprotein in 4 of 5 cases tested. Histologic examination revealed a fetal lung-like component as a focal finding accounting for 5% to 60% of the total tumor volume. It was invariably admixed with tissues having a morphology not resembling that of a fetal lung. A coexisting non-fetal lung-like element was quite heterogenous in appearance, showing various growth patterns. However, clear-cell (88%), hepatoid (29%), and large cell neuroendocrine carcinoma (24%) histology seemed overrepresented. HG-LAFM was characterized immunohistochemically by frequent expression of α-fetoprotein (41%), glypican-3 (88%), SALL-4 (59%), neuroendocrine markers (82%), CDX-2 (35%), and p53 (65%). HG-LAFM was molecularly heterogenous in that EGFR or KRAS mutation was observed in 22% of cases tested for both. Our data indicate that HG-LAFMs might form a coherent subgroup of lung adenocarcinomas. However, the uniformly focal nature of the fetal lung-like element, widely diverse coexisting non-fetal lung-like histology, and inhomogenous molecular profiles lead us to believe that HG-LAFM is best regarded as a morphologic pattern showing characteristic association with several clinicopathologic parameters rather than a specific tumor entity.
A case report of high-grade fetal lung adenocarcinoma with KRAS mutation.
Jiaqi W, Shicai Z, Bin Y, Yang W Respir Med Case Rep. 2024; 51:102049.
PMID: 39070297 PMC: 11279027. DOI: 10.1016/j.rmcr.2024.102049.
Shen L, Zhao J, Yang Y, Mu S, Yu Y, Han Y Transl Lung Cancer Res. 2024; 13(6):1407-1413.
PMID: 38973955 PMC: 11225042. DOI: 10.21037/tlcr-24-124.
Sun L, Guo W, Guo L, Chen X, Zhou H, Yan S NPJ Precis Oncol. 2024; 8(1):99.
PMID: 38831114 PMC: 11148097. DOI: 10.1038/s41698-024-00569-y.
Wu Y, Chen Y, Chuang J, Liao H Front Oncol. 2024; 14:1281211.
PMID: 38628667 PMC: 11018926. DOI: 10.3389/fonc.2024.1281211.
A component of high-grade fetal lung adenocarcinoma diagnosed as the cause of lymph node metastasis.
Ishii D, Aoyama S, Arai W, Hasegawa M, Tanaka A, Sakuraba M Thorac Cancer. 2024; 15(13):1112-1116.
PMID: 38528648 PMC: 11062867. DOI: 10.1111/1759-7714.15296.